Clinical Trial Update: A Randomized, Double-blind, Active Control, Parallel Group, Titration, Multicenter Study to Evaluate the Efficacy and Safety of Fimasartan [Phase 3]

View source ↗

Summary

Phase 3 randomized trial assessing efficacy and safety of fimasartan in chronic kidney disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Drugs mentioned

• Fimasartan (fimasartan)

Snippet

Sponsor: Boryung Pharmaceutical Co., Ltd | Conditions: Chronic Kidney Disease | Phase 3 | Status: COMPLETED